Cancer Cause and Prevention Research (93.393)
Cancer Cause and Prevention Research (Assistance Listing 93.393) is run by the National Institutes of Health, part of the Department of Health and Human Services. It awarded $3.6 billion in 2,517 grants from fiscal 2021 to 2025, about $1.4 million per award on average. 60 funding opportunities are open or forecast now.
The typical award was $1.1 million. Half of the 2,517 awards fell between $407,581 and $2.0 million, and they ranged from $0 to $15.4 million.
- Awarded, FY 2021 to 2025$3.6 billion
- Grant awards2,517
- Typical award$1.1 million
- Awarded in FY 2025$803 million
- Size rank113 of 1824
- Type of assistanceCooperative agreements, project grants
Key findings
- Annual funding rose from $647 million in fiscal 2021 to $803 million in fiscal 2025.
- It is the 113th largest of 1,824 federal grant programs by five-year awards.
- The 20 largest recipients received 38% of the money.
- Awards went to recipients in 48 states and territories.
What the program funds
To identify cancer risks and risk reduction strategies, to identify factors that cause cancer in humans, and to discover and develop mechanisms for cancer prevention and preventive interventions in humans. Research programs include: (1) chemical, physical and molecular carcinogenesis; (2) screening, early detection and risk assessment, including biomarker discovery, development and validation; (3) epidemiology; (4) nutrition and bioactive food components; (5) immunology and vaccines; (6) field studies and statistics; (7) cancer chemoprevention and interception; (8) pre-clinical and clinical agent development; (9) organ site studies and clinical trials; (10) health-related quality of life and patient-centered outcomes; and (11) supportive care and management of symptoms and toxicities. Small Business Innovation Research (SBIR) program: To expand and improve the SBIR program; to stimulate technical innovation; to increase private sector commercialization of innovations derived from Federal research and development funding; to increase small business participation in Federal research and development; and to foster and encourage participation in innovation and entrepreneurship by women and socially/economically disadvantaged persons. Small Business Technology Transfer (STTR) program: To stimulate and foster scientific and technological innovation through cooperative research and development carried out between small business concerns and research institutions; to foster technology transfer through cooperative research and development between small business concerns and research institutions; to increase private sector commercialization of innovations derived from Federal research and development funding, and foster participation in innovation and entrepreneurship by women and socially/economically disadvantaged persons.
Open opportunities
- Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R01 Clinical Trial Not Allowed)
- Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R21 Clinical Trials Not Allowed)
- Academic Research Enhancement Award (AREA) for Undergraduate-Focused Institutions (R15 Clinical Trial Required)
- Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required)
- National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required)
- Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R01 Clinical Trial Optional)
- Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R21 Clinical Trial Not Allowed)
- HEAL Initiative: Studies to Enable Analgesic Discovery (R61/R33 - Clinical Trial Not Allowed)
- Carcinogen Hazard Assessment Monographs Program (CHAMP) (R01 Clinical Trial Not Allowed)
- NIH, CDC and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Optional)
- NIH Small Business Technology Transfer Grant (Parent STTR [R41/R42] Clinical Trial Optional)
- Pancreatic Cancer Detection Consortium: Management and Data Coordination Unit (U24 Clinical Trial Not Allowed)
- Enhancing Mechanistic Research on Precision Probiotic Therapies (R61/R33 Clinical Trial Optional)
- Enhancing Mechanistic Research on Precision Probiotic Therapies (R33 Clinical Trial Optional)
- Change of Recipient Organization (Type 7 Parent Clinical Trial Optional)
- Successor-in-Interest (Type 6 Parent Clinical Trial Optional)
- NIH Support for Conferences and Scientific Meetings (Parent R13 Clinical Trial Not Allowed)
- Integrating Biospecimen Science Approaches into Clinical Assay Development (U01 Clinical Trial Not Allowed)
- Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research (U01 Clinical Trial Not Allowed)
- Early-Stage Development of Informatics Technologies for Cancer Research and Management (U01 Clinical Trial Optional)
- Research Enhancement Award Program (REAP) for Health Professional Schools and Graduate Schools (R15 Clinical Trial Required)
- Basic Research in Cancer Health Disparities (R21 Clinical Trial Not Allowed)
- Advancing Healthcare for Older Adults from Populations that Experience Health Disparities (R01 - Clinical Trial Optional)
- Mechanisms that Impact Cancer Risk after Bariatric Surgery (R01 Clinical Trial Optional)
- Mechanisms that Impact Cancer Risk after Bariatric Surgery (R21 Clinical Trial Not Allowed)
Rules from the program listing
Who can apply
The awardee will be a university, college, hospital, public agency, nonprofit research institution or for-profit organization that submits an application and receives a grant or cooperative agreement for support of research by a named principal investigator. SBIR grants can be awarded only to domestic small businesses (entities that are independently owned and operated for profit, are not dominant in the field in which research is proposed, and have no more than 500 employees). Primary employment (more than one- half time) of the principal investigator must be with the small business at the time of award and during the conduct of the proposed project. In both Phase I and Phase II, the research must be performed in the U.S. and its possessions. To be eligible for funding, a grant application must be approved for scientific merit and program relevance by a scientific review group and a national advisory council. STTR grants can be awarded only to domestic small business concern (entities that are independently owned and operated for profit, are not dominant in the field in which research is proposed and have no more than 500 employees) which "partner" with a research institution in cooperative research and development. At least 40 percent of the project is to be performed by the small business concern and at least 30 percent by the research institution. In both Phase I and Phase II, the research must be performed in the U.S. and its possessions.
What the money can and cannot pay for
Grants and cooperative agreements may be made to eligible institutions for the support of cancer research projects. The grants and cooperative agreements may be used for personnel, consultant costs, equipment, supplies, travel, patient costs, animals, alterations and renovations, miscellaneous items, and indirect costs. Restrictions are imposed against the use of funds for entertainment, foreign travel (unless specifically authorized), office equipment, and other items not normally necessary for the effective prosecution of such research. SBIR Phase I grants (of approximately 6-months' duration) are to establish the technical merit and feasibility of a proposed research effort that may lead to a commercial product or process. Phase II grants are for the continuation of the research initiated in Phase I, and that are likely to result in commercial products or processes. Only Phase I awardees are eligible to receive Phase II support. STTR Phase I grants (normally of 1-year duration) are to determine the scientific, technical, and commercial merit and feasibility of the proposed cooperative effort that has potential for commercial application. Phase II funding is based on results of research initiated in Phase I and scientific and technical merit and commercial potential of Phase II application.
Matching requirements
This program has no statutory formula. Matching requirements are not applicable to this assistance listing. MOE requirements are not applicable to this assistance listing.
Award range and average, in the agency's words
Range: $927 to $3,046,580 Average: $568,686
Funding history and past recipients
From fiscal 2021 to 2025, Cancer Cause and Prevention Research (93.393) awarded$3.6 billion across 2,517 grant awards, an average of $1.4 million per award.
Who usually wins
Colleges and universities received 66% of the money, nonprofits 28% and small businesses 1.8%.
| Recipient type | Awards | Amount | Share |
|---|---|---|---|
| Colleges and universities | 1,691 | $2.4 billion | 66% |
| Nonprofits | 655 | $1.0 billion | 28% |
| Other | 100 | $143 million | 4.0% |
| Small businesses | 62 | $65.9 million | 1.8% |
| Tribal governments and organizations | 4 | $5.5 million | 0.1% |
| State and local governments | 5 | $4.8 million | 0.1% |
By state
46 states have a page for this program: those that received at least $1 million or 10 awards.
| State | Awards | Amount |
|---|---|---|
| California | 273 | $465 million |
| New York | 295 | $445 million |
| Massachusetts | 220 | $351 million |
| Texas | 206 | $270 million |
| Pennsylvania | 133 | $175 million |
| Tennessee | 84 | $151 million |
| North Carolina | 116 | $149 million |
| Minnesota | 81 | $138 million |
| Washington | 84 | $123 million |
| Ohio | 72 | $105 million |
| Florida | 72 | $99.7 million |
| Michigan | 65 | $89.5 million |
| Illinois | 71 | $87.0 million |
| Georgia | 50 | $61.3 million |
| District of Columbia | 45 | $61.2 million |
| Missouri | 47 | $60.9 million |
| Wisconsin | 30 | $60.6 million |
| Utah | 37 | $57.4 million |
| South Carolina | 39 | $54.8 million |
| New Jersey | 38 | $54.2 million |
| Connecticut | 51 | $53.8 million |
| Virginia | 49 | $50.3 million |
| Maryland | 51 | $47.6 million |
| Colorado | 39 | $46.2 million |
| Alabama | 30 | $40.9 million |
| Arizona | 25 | $36.8 million |
| Hawaii | 10 | $33.9 million |
| Indiana | 18 | $24.0 million |
| Vermont | 10 | $22.4 million |
| Kansas | 11 | $21.4 million |
| Oregon | 19 | $20.8 million |
| Iowa | 10 | $17.4 million |
| Oklahoma | 14 | $14.2 million |
| New Hampshire | 11 | $14.0 million |
| Kentucky | 19 | $12.0 million |
| Rhode Island | 23 | $9.1 million |
| Nebraska | 9 | $8.4 million |
| New Mexico | 5 | $8.3 million |
| Louisiana | 9 | $7.0 million |
| Delaware | 3 | $6.0 million |
| Maine | 3 | $4.0 million |
| Alaska | 3 | $3.7 million |
| South Dakota | 3 | $3.1 million |
| Puerto Rico | 2 | $2.9 million |
| Mississippi | 3 | $2.4 million |
| Arkansas | 3 | $2.3 million |
| Montana | 1 | $355,259 |
| West Virginia | 3 | $244,264 |